Update on asthma medications

Nurse Practitioner, Jun 2002 by Runton, Nancy

18. Singulair prescribing information. Whitehouse Station, N.J.: Merck & Co., Inc.; 2001.

19. Ventolin product information. Research Triangle Park, N.C.: GlaxoSmithKline; August 2001. 20. Proventil HFA product information. Kenilworth, NJ.: Schering Corporation; January 2000. 21. Xopenex full prescribing information. Marlborough, Mass.: Sepracor Inc. Available at: http://www.xopenex.com/fullPres.html. Accessed January 30, 2002.

22. Pediapred prescribing information. Rochester, N.Y.: Celltech Pharmaceuticals, Inc.; 2001. 23. Prelone prescribing information. Tewksbury, Mass.: Muro Pharmaceutical Inc; January 1999. 24. Handley DA, Morley J: The pursuit of precison pharmaceuticals: divergent effects of P2-agonist isomers. Expert Opin Investig Drugs 1998;7(10):1601-16.

25. Mitra S, Ugur M, Ugur 0, et al.: (S)-Albuterol increases intracellular free calcium by mus

carinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 1998;53(3):347-54.

26. Nelson HS, Bensch G, Pleskow WW, et al.: Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. I Allergy Clin Immunol 1998;102(6, pt 1):943-52.

27 Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL: Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol 1996;14:37-45.

28. Perrin-Fayolle M. Salbutamol in the treatment of asthma [letter]. Lancet 1995;346:1101. 29. Volcheck GW, Gleich GJ, Kita H: Pro- and anti-inflammatory effects of beta adrenergic agonists on eosinophil response to IL-5. J Allergy Clin Immunol 1998;10]:535.

30. Walle T, Walle UK, Thornburg KR, Schey KL: Stereoselective sulfation of albuterol in humans. Biosynthesis of the sulfate conjugate by HEP G2 cells. Drug Metab Dispos 1993;21:76-80.

31. Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ: Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol 1998;38:1096-1106.

32. FDA's policy statement for the development of new stereoisomeric drugs. Chirality 1992;4:338-40.

33. Milgrom H, Skoner DP, Bensch G, et al.: Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001;108:938-45.

34. Carl J, Myers T, Kercsmar C: Comparison of levalbuterol and racemic albuterol for treatment of acute asthma in pediatric patients. Presented at: Chest 2001, Annual Meeting of the American College of Chest Physicians; November 5, 2001; Philadelphia, Pa.

35. Advair Diskus product information. Research Triangle Park, N.C.: Glaxo Wellcome Inc; August 2000.

36. Kavuru M, Melamed J, Gross G, et al.: Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;105(6 Pt 1):1108-16.

Nancy Runton, CRNP, MSN

Nancy Runton, CRNP, MSN, is a Pediatric Nurse Practitioner at Virginia Pediatric Group, LTD, Fairfax Va., and the owner of Runton Associates, Alexandria, Va.; http://www.PediatricHealth.org.